Your browser doesn't support javascript.
loading
Co-Administration with Voriconazole Doubles the Exposure of Ruxolitinib in Patients with Hematological Malignancies.
Zhao, Yingxin; Chen, Peng; Dou, Liping; Li, Fei; Li, Meng; Xu, Lingmin; Chen, Jing; Jia, Mingyu; Huang, Sai; Wang, Nan; Luan, Songhua; Yang, Jinling; Bai, Nan; Liu, Daihong.
Afiliação
  • Zhao Y; Medical School of Chinese PLA, Beijing, People's Republic of China.
  • Chen P; Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, People's Republic of China.
  • Dou L; Medical School of Chinese PLA, Beijing, People's Republic of China.
  • Li F; Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, People's Republic of China.
  • Li M; The Second School of Clinical Medicine, Southern Medical University, Guangzhou, People's Republic of China.
  • Xu L; Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, People's Republic of China.
  • Chen J; Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, People's Republic of China.
  • Jia M; Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, People's Republic of China.
  • Huang S; Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, People's Republic of China.
  • Wang N; Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, People's Republic of China.
  • Luan S; Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, People's Republic of China.
  • Yang J; Medical School of Chinese PLA, Beijing, People's Republic of China.
  • Bai N; Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, People's Republic of China.
  • Liu D; Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, People's Republic of China.
Drug Des Devel Ther ; 16: 817-825, 2022.
Article em En | MEDLINE | ID: mdl-35370398
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirimidinas / Neoplasias Hematológicas Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Drug Des Devel Ther Assunto da revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2022 Tipo de documento: Article País de publicação: Nova Zelândia
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirimidinas / Neoplasias Hematológicas Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Drug Des Devel Ther Assunto da revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2022 Tipo de documento: Article País de publicação: Nova Zelândia